Alex C. Sapir is the current CEO and President of Fulcrum Therapeutics, Inc., having stepped into the role on July 1, 2023. Previously, he led ReViral Ltd., a biopharmaceutical firm that specialized in antiviral treatments until its acquisition by Pfizer...
Alex C. Sapir is the current CEO and President of Fulcrum Therapeutics, Inc., having stepped into the role on July 1, 2023. Previously, he led ReViral Ltd., a biopharmaceutical firm that specialized in antiviral treatments until its acquisition by Pfizer in 2022. With a Bachelor's degree in Economics from Franklin and Marshall College and an MBA from Harvard Business School, Sapir combines practical business training with experience in the biotechnology sector. His career includes serving as CEO of Dova Pharmaceuticals, where he focused on treatments for rare diseases and worked as Executive Vice President at United Therapeutics. Notably, he has a significant stake in Fulcrum’s growth—recent trading showed a dramatic increase in his stock holdings, with transactions that reached up to $22.39 million in one month alone. His compensation for 2023 was $990,596, which reflects a mix of salary and performance bonuses. What’s interesting is that despite entering the role mid-year, he quickly earned a bonus for his work and ongoing efforts to guide the company towards its business goals.